• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年人特应性皮炎:治疗选择的综述。

Atopic Dermatitis in Older Adults: A Review of Treatment Options.

机构信息

Department of Dermatology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, 35-2 Sakaecho, Itabashi, Tokyo, 173-0015, Japan.

出版信息

Drugs Aging. 2020 Mar;37(3):149-160. doi: 10.1007/s40266-020-00750-5.

DOI:10.1007/s40266-020-00750-5
PMID:32086792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7044141/
Abstract

Atopic dermatitis (AD) in older adults (elderly AD) has recently emerged as a newly defined subgroup of AD. When selecting treatment options, clinical characteristics of elderly AD and age-specific factors of older patients must be considered. As in other age groups, regular application of moisturizers in combination with topical corticosteroids and calcineurin inhibitors, adjunctive administration of oral antihistamines/anti-allergic drugs, and avoidance of exacerbating factors comprise basic treatments for elderly AD. For moderate-to-severe cases and/or in those with a decreased ability to use topical treatments, powerful anti-inflammatory treatments may become necessary as additional treatment options. While low-dose oral corticosteroids may be useful for cases of elderly AD, careful attention should be paid to adverse effects. Oral cyclosporine (ciclosporin) is less commonly used due to the increased risk of malignancy and organ toxicity in older patients with AD. Narrow-band ultraviolet B phototherapy may also be useful for older patients, although the necessity of frequent hospital visits for irradiation therapy may become a burden of disease for such patients. As a biologic, dupilumab therapy markedly improves skin lesions and itch in older patients with AD, with a rapid response and non-serious adverse effects. Nevertheless, injection pain, expensive medical care, and regular follow-up every 2 weeks are disadvantages of dupilumab therapy. Therefore, clinicians must prioritize individualized treatment options that will reduce the burden of disease for cases of elderly AD.

摘要

特应性皮炎(AD)在老年人(老年 AD)中最近出现了一个新的亚组。在选择治疗方案时,必须考虑老年 AD 的临床特征和老年患者的年龄特异性因素。与其他年龄组一样,常规使用保湿剂联合外用皮质类固醇和钙调神经磷酸酶抑制剂、辅助给予口服抗组胺药/抗过敏药物以及避免加重因素是老年 AD 的基本治疗方法。对于中重度病例和/或外用治疗能力下降的患者,可能需要额外的强效抗炎治疗。虽然低剂量口服皮质类固醇可能对老年 AD 病例有用,但应注意不良反应。由于 AD 老年患者发生恶性肿瘤和器官毒性的风险增加,环孢素(环孢菌素)口服制剂的使用较少。窄谱中波紫外线光疗也可能对老年患者有用,尽管频繁到医院进行辐照治疗可能会给这些患者带来疾病负担。作为一种生物制剂,度普利尤单抗治疗可显著改善老年 AD 患者的皮肤病变和瘙痒,起效迅速,不良反应非严重。然而,注射疼痛、昂贵的医疗费用和每 2 周定期随访是度普利尤单抗治疗的缺点。因此,临床医生必须优先考虑个体化的治疗方案,以减轻老年 AD 病例的疾病负担。

相似文献

1
Atopic Dermatitis in Older Adults: A Review of Treatment Options.老年人特应性皮炎:治疗选择的综述。
Drugs Aging. 2020 Mar;37(3):149-160. doi: 10.1007/s40266-020-00750-5.
2
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).度普利尤单抗联合外用皮质类固醇治疗对环孢素 A 应答不足或不耐受或当这种治疗在医学上不建议时的中重度特应性皮炎成人患者:一项安慰剂对照、随机 III 期临床试验(LIBERTY AD CAFÉ)。
Br J Dermatol. 2018 May;178(5):1083-1101. doi: 10.1111/bjd.16156. Epub 2018 Mar 25.
3
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗中重度特应性皮炎的长期管理(LIBERTY AD CHRONOS):一项为期 1 年、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
4
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.在长达 4 年的时间里,接受度普利尤单抗治疗的中重度特应性皮炎成人患者的总体感染风险没有增加。
Adv Ther. 2023 Jan;40(1):367-380. doi: 10.1007/s12325-022-02322-y. Epub 2022 Nov 1.
5
Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.地氯雷他定联合糠酸莫米松治疗 6 月龄至 5 岁中重度特应性皮炎儿童的疗效和安全性。
Adv Ther. 2024 Mar;41(3):1046-1061. doi: 10.1007/s12325-023-02753-1. Epub 2024 Jan 9.
6
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.阿泊替尼治疗早期瘙痒反应与中重度特应性皮炎患者的后期疗效结局相关:随机 III 期 JADE COMPARE 试验的亚组分析。
Am J Clin Dermatol. 2023 Jan;24(1):97-107. doi: 10.1007/s40257-022-00738-4. Epub 2022 Dec 13.
7
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.一项为期 16 周的随机 III 期研究:度普利尤单抗对 6 个月至 5 岁中重度特应性皮炎儿童的实验室安全性。
Paediatr Drugs. 2023 Jan;25(1):67-77. doi: 10.1007/s40272-022-00553-8. Epub 2022 Dec 19.
8
Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective.巴瑞替尼与度普利尤单抗治疗中度至重度特应性皮炎的成本效益分析:意大利医疗保健系统视角
J Med Econ. 2023 Jan-Dec;26(1):1155-1166. doi: 10.1080/13696998.2023.2255495. Epub 2023 Sep 7.
9
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.度普利尤单抗联合局部皮质类固醇治疗青少年和成人中重度特应性皮炎(AD Up)的安全性和有效性:一项随机、双盲、安慰剂对照、3 期临床试验的结果。
Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21.
10
Topical tacrolimus for atopic dermatitis.外用他克莫司治疗特应性皮炎。
Cochrane Database Syst Rev. 2015 Jul 1;2015(7):CD009864. doi: 10.1002/14651858.CD009864.pub2.

引用本文的文献

1
Mesenchymal Stromal Cell-Derived Extracellular Vesicles in the Management of Atopic Dermatitis: A Scoping Review of Therapeutic Opportunities and Challenges.间充质基质细胞衍生的细胞外囊泡在特应性皮炎治疗中的应用:治疗机会与挑战的范围综述
Int J Nanomedicine. 2025 Mar 4;20:2673-2693. doi: 10.2147/IJN.S494574. eCollection 2025.
2
Role of Polyphenols in Dermatological Diseases: Exploring Pharmacotherapeutic Mechanisms and Clinical Implications.多酚在皮肤病中的作用:探索药物治疗机制及临床意义
Pharmaceuticals (Basel). 2025 Feb 12;18(2):247. doi: 10.3390/ph18020247.
3
Preparation of Patchouli Oil Microemulsion Gel and Its Topical Application to Ameliorate Atopic Dermatitis in Mice.

本文引用的文献

1
Dupilumab facial redness: Positive effect of itraconazole.度普利尤单抗引起的面部发红:伊曲康唑的积极作用。
JAAD Case Rep. 2019 Oct 22;5(10):888-891. doi: 10.1016/j.jdcr.2019.07.020. eCollection 2019 Oct.
2
Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis.老年特应性皮炎患者血液中心血管和动脉粥样硬化标志物增加。
Ann Allergy Asthma Immunol. 2020 Jan;124(1):70-78. doi: 10.1016/j.anai.2019.10.013. Epub 2019 Oct 14.
3
Clinical practice guidelines for the management of atopic dermatitis 2018.
广藿香精油微乳凝胶的制备及其局部应用对改善小鼠特应性皮炎的作用
Gels. 2024 Dec 5;10(12):796. doi: 10.3390/gels10120796.
4
Controlled Release of Madecassoside and Asiaticoside of L. Origin from Sustainable Cold-Processed Topical Formulations.可持续冷加工外用制剂中源自L.的积雪草苷和羟基积雪草苷的控释
Molecules. 2024 Nov 26;29(23):5583. doi: 10.3390/molecules29235583.
5
Hormonal interventions in skin wounds - a mini review.皮肤伤口的激素干预 - 小型综述。
Mol Med. 2024 Nov 14;30(1):217. doi: 10.1186/s10020-024-00978-6.
6
Association Between Atopic Dermatitis and Impaired Mobility among Adults in the United States: Findings from the 2001-2006 National Health and Nutrition Examination Survey.美国成年人特应性皮炎与行动能力受损之间的关联:2001 - 2006年国家健康和营养检查调查结果
J Clin Aesthet Dermatol. 2024 Jun;17(6):58-60.
7
Topical steroids or emollients: does order matter?局部用皮质类固醇或保湿剂:顺序重要吗?
Arch Dermatol Res. 2024 Mar 15;316(4):104. doi: 10.1007/s00403-024-02837-0.
8
ATI-1777, a Topical Jak1/3 Inhibitor, May Benefit Atopic Dermatitis without Systemic Drug Exposure: Results from Preclinical Development and Phase 2a Randomized Control Study ATI-1777-AD-201.ATI-1777,一种局部用Jak1/3抑制剂,可能在不引起全身药物暴露的情况下对特应性皮炎有益:临床前开发和2a期随机对照研究ATI-1777-AD-201的结果
JID Innov. 2023 Nov 28;4(2):100251. doi: 10.1016/j.xjidi.2023.100251. eCollection 2024 Mar.
9
Kappa opioid agonists in the treatment of itch: just scratching the surface?κ阿片受体激动剂在瘙痒治疗中的应用:只是触及表面?
Itch (Phila). 2023 Oct-Dec;8(4). doi: 10.1097/itx.0000000000000072. Epub 2023 Dec 6.
10
Current and Emerging Therapies for Atopic Dermatitis in the Elderly.老年人特应性皮炎的现有和新兴疗法。
Clin Interv Aging. 2023 Oct 2;18:1641-1652. doi: 10.2147/CIA.S426044. eCollection 2023.
2018 年特应性皮炎管理临床实践指南。
J Dermatol. 2019 Dec;46(12):1053-1101. doi: 10.1111/1346-8138.15090. Epub 2019 Oct 9.
4
Atopic dermatitis in elderly adults.老年人特应性皮炎。
Eur J Dermatol. 2019 Aug 1;29(4):371-374. doi: 10.1684/ejd.2019.3609.
5
Characterizing dupilumab facial redness: A multi-institution retrospective medical record review.度普利尤单抗所致面部发红的特征:一项多机构回顾性病历审查。
J Am Acad Dermatol. 2020 Jan;82(1):230-232. doi: 10.1016/j.jaad.2019.06.026. Epub 2019 Jun 19.
6
Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks.老年人特应性皮炎:临床与病理生理特征综述
Br J Dermatol. 2020 Jan;182(1):47-54. doi: 10.1111/bjd.17896. Epub 2019 Jul 28.
7
Distribution of atopic dermatitis lesions in United States adults.美国成年人特应性皮炎皮损的分布。
J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1341-1348. doi: 10.1111/jdv.15574. Epub 2019 Apr 15.
8
Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis.在使用度普利尤单抗治疗特应性皮炎的患者中出现结膜炎并伴有结膜增殖性病变。
Allergol Int. 2019 Jul;68(3):383-384. doi: 10.1016/j.alit.2018.12.012. Epub 2019 Feb 2.
9
Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis.中重度特应性皮炎患者的分子表型在年龄特异性上的变化。
J Allergy Clin Immunol. 2019 Jul;144(1):144-156. doi: 10.1016/j.jaci.2019.01.015. Epub 2019 Jan 24.
10
Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema.口服H1抗组胺药作为湿疹局部治疗的“附加”疗法。
Cochrane Database Syst Rev. 2019 Jan 22;1(1):CD012167. doi: 10.1002/14651858.CD012167.pub2.